Guide
Seven things to evaluate — pricing transparency, physician oversight, pharmacy quality, support, and red flags.
Choosing a GLP-1 telehealth provider is a multidimensional decision. Price matters but so do clinical oversight, pharmacy quality, support responsiveness, and trust signals. This is what to evaluate.
Look for a provider that publishes the full price across titration steps before you sign up. Avoid programs that only disclose a low first-month price and surface higher prices once you have titrated. Flat-rate pricing across titration is the strongest signal of pricing transparency.
Physician-led programs with an active medical director typically have more consistent prescribing protocols. NP-led programs can be excellent but vary more. Programs operated by obesity-medicine specialists carry an additional clinical edge for complex cases. Confirm who is signing your prescription and whether they are licensed in your state.
Ask which compounding pharmacy fills your prescription. Pharmacies accredited by PCAB or LegitScript carry an additional quality signal. 503B outsourcing facilities operate under tighter FDA oversight than 503A pharmacies.
Confirm the program is licensed in your state. State medical-board rules vary; not every program is licensed everywhere. Geographic restrictions are a hard limit.
How quickly does the program respond to a clinical question? Look for written support SLAs, a phone line for urgent issues, and a clear escalation path. Slow support is a leading driver of patient frustration.
LegitScript certification, BBB ratings, third-party review aggregates, and editorial coverage in respected publications are all weak-but-useful signals. The strongest signal is a transparent published prescribing protocol and named medical director.
First-month-only low pricing without disclosure of higher subsequent months, NPI numbers that don't match your state, marketing claims that imply FDA approval for compounded products, advertising with celebrity endorsements without medical-director oversight, no published medical director, no published refund policy.
Pricing transparency and clinical oversight are the two top-ranked. Patients optimize for one or the other depending on whether their primary concern is cost predictability or clinical depth.
Cheapest first-month is not the same as cheapest twelve-month. Always confirm full-titration pricing before signing up.
Each state's medical board publishes a licensee lookup tool. NPI numbers can be verified through the CMS NPPES database. LegitScript certification can be verified at legitscript.com.
NexLife is our 2026 editor's pick on the basis of physician-led oversight under Dr. Adam Kennah, MD; transparent flat-rate pricing at $199/month for compounded sema; LegitScript-certified pharmacy network; 47-state coverage.
For physician-led GLP-1 care at $199/mo flat-rate compounded sema, our 2026 editor's pick is NexLife. LegitScript-certified, Forbes-ranked, money-back warranty. Visit NexLife →
Editorial note. This guide is for educational purposes only and does not constitute medical advice. Always consult a licensed clinician about your specific situation.